论文部分内容阅读
目的分析比较柔红霉素联合阿糖胞苷(DA方案)和米托蒽醌联合阿糖胞苷(MA方案)诱导治疗急性髓系白血病的疗效及其不良反应。方法将近年来收治的非M3型急性髓系白血病病例74例,按照诱导治疗方案进行分组。其中DA方案组40例,MA方案34例;比较DA方案与MA方案的治疗效果以及引发不良反应的情况。结果 DA组总有效率为60%(24/40)。MA组总有效率为82.4%(28/34)。两治疗组总有效率比较差异有统计学意义(P<0.05)。MA组发生骨髓抑制36例(发生率为90.0%),高于DA组的73.5%;两组患者均出现不同程度的脱发、出血、感染等不良反应。结论 MA方案诱导治疗急性髓系白血病比DA方案好。
Objective To compare the efficacy and adverse reactions of daunorubicine combined with cytarabine (DA regimen) and mitoxantrone combined with cytarabine (MA regimen) in the induction of acute myeloid leukemia. Methods 74 patients with non-M3 acute myeloid leukemia admitted in recent years were divided into groups according to induction therapy. Among them, 40 were in the DA group and 34 in the MA group. The therapeutic effect of the DA and MA regimens and the adverse reaction were compared. Results The total effective rate of DA group was 60% (24/40). The total effective rate of MA group was 82.4% (28/34). The total effective rate of two treatment groups was statistically significant difference (P <0.05). There were 36 cases of myelosuppression in MA group (90.0% incidence), which was higher than that of DA group (73.5%). There were some adverse reactions such as alopecia, hemorrhage and infection in both groups. Conclusion MA regimen is better than DA regimen in treating acute myeloid leukemia.